Harry Erba, MD, PhD

home / authors / harry-erba-md-phd

Harry Erba, MD, PhD, is a professor of medicine at Duke Cancer Institute, chair of the SWOG Leukemia Committee and co-chair of the myeloMATCH Senior Science Council.

Articles

Erba Explores myeloMATCH Substudies Targeting Genetic Diversity in AML, MDS

Harry Erba, MD, PhD

November 20th 2024

Harry Erba, MD, PhD, discusses the specific substudies included in myeloMATCH.

Behind myeloMATCH: A Precision Medicine Trial in AML and MDS

Harry Erba, MD, PhD

July 30th 2024

Harry Erba, MD, PhD, discusses myeloMATCH, a precision medicine umbrella trial for patients with acute myeloid leukemia or myelodysplastic syndrome.

Exploring Alternative FLT3 Inhibitors for AML

Harry Erba, MD, PhD

December 7th 2023

Harry Erba, MD, PhD, discusses the recent quizartinib plus chemotherapy approval from the FDA for patients with newly-diagnosed FLT3-internal tandem duplication-positive acute myeloid leukemia.

Using MRD to Guide Therapy in AML

Harry Erba, MD, PhD

September 16th 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses using MRD to guide therapy in acute myeloid leukemia (AML).

FLT3 Inhibitors in Development for AML

Harry Erba, MD, PhD

May 29th 2014

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).

Tipifarnib for the Treatment of Older Patients With AML

Harry Erba, MD, PhD

March 12th 2014

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses tipifarnib for the treatment of older, untreated patients with AML.